Intuitive Surgical, Inc. vs Revvity Inc — how do they compare? Intuitive Surgical, Inc. trades at $423.96 (market cap $146.76B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Intuitive Surgical, Inc. is far larger — about 8.6× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Revvity Inc for 12 Days on average.
| ISRG | RVTY | |
|---|---|---|
Market Cap | $146.76B | $16.98B |
Volume | 2,529,814 | 1,456,900 |
Sector | Health | Health |
52-Week High | $592.85 | $157.36 |
52-Week Low | $332.02 | $82.26 |
Typical Hold Time | 84 Days | 12 Days |
Enterprise Value | $141.54B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 0.21% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.80, and has shown consistent revenue growth, reaching $10.06B in 2025. Analyst consensus is strongly bullish with a $480.78 price target, though the stock faces headwinds from slower procedure growth in some markets.
The outlook for ISRG remains positive due to its dominant position in robotic surgery, expanding international presence, and high recurring revenue. Key risks include competitive pressures, regulatory hurdles, and economic sensitivity affecting procedure volumes. With solid fundamentals and analyst support, the stock offers growth potential, but investors should monitor execution against these risks.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →